NasdaqGS - Nasdaq Real Time Price USD

Boundless Bio, Inc. (BOLD)

10.77 -0.26 (-2.36%)
As of 11:00 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jonathan E. Lim M.D. Co-Founder & Independent Chairman -- -- 1972
Mr. Zachary Hornby CEO, President & Director 721.05k -- 1979
Dr. Christian Hassig Ph.D. Chief Scientific Officer 563.55k -- 1973
Dr. Klaus W. Wagner M.D., Ph.D. Chief Medical Officer 633.08k -- 1973
Ms. Jessica Oien J.D. Chief Legal Officer & Corporate Secretary -- -- 1972
Mr. Neil Abdollahian M.B.A., M.S. Chief Business Officer -- -- 1973
Mr. Anthony Pinkerton Ph.D. Senior Vice President of Drug Discovery -- -- --
Ms. Meredith Wesley Senior Vice President of Talent & Culture -- -- --
Dr. Shailaja Kasibhatla Ph.D. Senior Vice President of Discovery & Translational Development -- -- --
Dr. Peter Krein Ph.D. Senior Vice President of Precision Medicine -- -- --

Boundless Bio, Inc.

9880 Campus Point Drive
Suite 120
San Diego, CA 92121
United States
(858) 766-9912 https://boundlessbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
72

Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Corporate Governance

Boundless Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 02, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Mar 28, 2024
    S-8: Offering Registrations
    See Full Filing
  • Mar 25, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Mar 22, 2024
    8-A12B: Trading Registrations
    See Full Filing
  • Mar 21, 2024
    S-1/A: Offering Registrations
    See Full Filing

Upcoming Events

Related Tickers

ANRO Alto Neuroscience, Inc.
13.94
-1.80%
 
CTNM Contineum Therapeutics, Inc.
15.46
-2.95%
 
NMRA Neumora Therapeutics, Inc.
9.19
-4.22%
 
CGEM Cullinan Therapeutics, Inc.
18.92
+0.13%
 
AVBP ArriVent BioPharma, Inc.
14.80
-3.27%
 
TRML Tourmaline Bio, Inc.
15.01
-2.60%
 
MGX Metagenomi, Inc.
6.76
+0.07%
 
PEPG PepGen Inc.
11.42
-3.51%
 
NBTX Nanobiotix S.A.
5.90
0.00%
 
TYRA Tyra Biosciences, Inc.
15.09
-5.69%